Additional staff, faster template development and yet more emergency use authorizations (EUAs) are among the tools the US Food and Drug Administration plans to deploy as part of its unprecedented response to the ongoing COVID-19 pandemic, device center leaders said during a 15 April webinar aimed at diagnostics firms.
The webinar highlighted the rapid growth in COVID-19 diagnostics and treatments. The agency is hiring employees to monitor and respond to messages from developers interested in pursuing COVID-19-related EUAs, said...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?